

UCSF

UC San Francisco Electronic Theses and Dissertations

Title

Post-transcriptional effector domains in the Rev proteins of feline immunodeficiency virus and equine infectious anemia virus

Permalink

<https://escholarship.org/uc/item/13w186c9>

Author

Manucuso, Victoria Alexandra

Publication Date

1995

Peer reviewed|Thesis/dissertation

**POST-TRANSCRIPTIONAL EFFECTOR DOMAINS
IN THE REV PROTEINS OF FELINE IMMUNODEFICIENCY VIRUS
AND EQUINE INFECTIOUS ANEMIA VIRUS**

by
Victoria Alexandra Mancuso

A Thesis

Submitted in partial satisfaction of the requirements for the M.D. with Thesis
Program

of the
University of California, San Francisco




Table of Contents


<u>Abstract</u>	iii
<u>List of Figures/Tables</u>	iv-xiv
<u>Introduction</u>	1
<u>Methods</u>	3
<u>Results</u>	5
<u>Discussion</u>	7
<u>References</u>	8-9
<u>Acknowledgements</u>	10


Abstract

The lifecycle of all retroviruses depends upon their ability to deliver unspliced or incompletely-spliced viral RNAs into the cytoplasm of an infected cell. To carry out this critical function, many retroviruses produce specific regulatory proteins that bind to viral RNAs in the nucleus and allow them to enter the cytoplasm before splicing is completed. These posttranscriptional *trans*-activators, which include the human immunodeficiency virus type 1 (HIV-1) Rev and human T-cell leukemia virus type I (HTLV-I) Rex proteins, are of interest not only because their mechanism of action is unknown, but also as potential targets for antiretroviral therapy. Along with the peptide sequences needed for nuclear localization and RNA binding, HIV-1 Rev and HTLV-I Rex each contain a discrete regulatory domain, called an effector domain, that is indispensable for function. The Rev and Rex effector domains are thought to mediate contact with an unknown cellular cofactor, and can substitute for one another *in vivo*. Using a functional assay, we have now obtained evidence that equivalent effector domains are also present in several, and perhaps all, other proteins of this type. In each case, effector activity maps to a single region no more than 30 amino acids long. Most effector domains coincide with a short, discontinuous array of leucines or other bulky hydrophobic residues that are critical for biological activity, as observed previously in the HIV-1 Rev effector. However, we find that effector peptides from the equine infectious anemia virus (EIAV) and feline immunodeficiency virus (FIV) Rev proteins appear distinct, as they lack this clustering of hydrophobic residues, contain a somewhat higher proportion of polar residues, and are especially rich in basic amino acids (13%-22% vs. 2%). Site-directed mutagenesis confirms that the specific residues needed for function of the EIAV and FIV domains differ from those of other effector regions. Taken together, our findings help to define the sequence requirements for effector domain activity, support the view that such domains are present in all Rev- or Rex-like proteins, and suggest the existence of two structurally distinct but functionally interchangeable families of effector domains.

List of Figures/Tables


Figure 1. Mapping the minimal effector peptide in FIV Rev. **A)** Functional characterization of HIV-FIV fusion proteins. Autoradiogram at right indicates the levels of CAT enzyme expression in CV1 cells that had been cotransfected with the Rev-inducible CAT reporter plasmid pDM128, along with derivatives of the HIV-1 Rev expression vector pRSV-Rev encoding each of the constructs shown schematically at left. Small open rectangles in the 116 amino-acid HIV-1 Rev protein (shaded rectangle) represent the essential N-terminal, arginine-rich, and C-terminal effector regions, respectively (6,12,14). Fusion constructs were created by replacing HIV-1 *rev* codons 78-114 by a BglIII linker, and then inserting the indicated codons from FIV *rev* into this BglIII site. FIV *rev* sequences (large open rectangle) were subcloned using the polymerase chain reaction (PCR.) **B)** Mutational inactivation and immunoblot analysis of an HIV-FIV Rev fusion protein containing the minimal FIV effector domain (FIV residues 95-121). At left, CAT expression in cells transfected with this minimal construct (HIV-FIV), or with a mutant of the same construct in which FIV residues 103 and 104 (AspLeu) were replaced by alanines. At right, immunoblot detection of HIV-1 Rev and of the indicated fusion proteins (arrow) in transiently-transfected cells, using an antibody specific for HIV-1 Rev (a gift from M.L. Zapp.) Plasmid construction, mutagenesis, and transfection assays were performed as described (5-7). All CAT assays were normalized to β -galactosidase activity expressed from a co-transfected internal control plasmid. Sham = sham-transfected cells; None = cells transfected with pDM128 alone.






A

Figure 2. Mapping the minimal effector peptide in EIAV Rev. **A)** Functional characterization of a series of HIV-EIAV fusion proteins. Large open rectangles represent sequences from the 164-amino-acid EIAV Rev. **B)** Mutational analysis of the minimal EIAV effector region (EIAV *rev* residues 32-55) in the context of the HIV-EIAV fusion. Fusion proteins were constructed that contained either the wild-type EIAV peptide (wt) or dicodon mutations that replaced each of the indicated dipeptides with alanine pairs. CAT activity induced by each construct is expressed as a multiple of CAT activity in cells receiving pDM128 alone, and corresponds to the mean of duplicate determinations. **C)** Immunoblot detection of HIV-1 Rev, HIV-EIAV containing the minimal EIAV effector domain, and mutants of the latter in which alanines replace the indicated dipeptides in EIAV. Methods are as described for Fig. 1.





HIV Rev →
HIV-EIAV →




Figure 3. The hybrid HIV-EIAV and HIV-FIV Rev proteins induce expression of unspliced RRE-containing transcripts in the cytoplasm. Each lane contains 15 μ g of total cytoplasmic RNA isolated from COS cells 48 hr after transfection with carrier DNA (Sham), or with pDM128 either alone (None) or together with vectors encoding HIV-1 Rev or the minimal HIV-EIAV or HIV-FIV fusion proteins. Northern blots were performed and probed essentially as described (7). The ratios of unspliced to spliced RNA in lanes 2-5 are 0.77, 4.1, 2.6, and 1.9, respectively, as determined by quantitative phosphorimaging.



Figure 4. Minimal functional effector domains from the Rev proteins of complex retroviruses. The sequences shown are the minimal active effector peptides from HIV-1, HTLV-I, FIV, ELAV, Visna virus, HIV type 2, and the african green monkey strain of simian immunodeficiency virus (SIV_{agm}).

Each can substitute functionally for the HIV-1 effector domain in the co-transfection assay described in Figs. 1 and 2 (7, and Hope et al. manuscript in preparation.) The leucine-rich effectors each contain a cluster of four or five hydrophobic residues (leucine, isoleucine, or methionine) within an 11-residue region; mutational analysis indicates that these clustered residues are essential for effector activity (14, and Hope et al. manuscript in preparation.)

Leucine-rich Effectors

HIV-1 61- STYLGRSAEPVPIQLPPLERLITLDCNEDCG -90
HTLV-I 80- DALSAQLYSSLSLDSPPS -98
Visna 93- ADLQWFYPNMESNMVGMEMLITLETQLEDNA -122
HIV-2 64- PADSPLDQTIQHLQGLTIQELPDP -87
SIV_{agm} 58- QVYAVDRLADEAQHLAIQQLPDPPHSA -84

Polar Effectors

FIV 95- LAFKKMMTDLEDRFRKLFSGSPSKDEYT -120
EIAV 32- PQGPLESDQWCRVLRQSLPEEKIP -55

Introduction

Retroviruses that have complex, multi-intronic genomes face a predicament upon infecting a cell: the sequences encoding the major structural proteins (Gag, Pol and Env) of these viruses are contained within potential introns, and so would normally be spliced out of any nascent viral mRNA before it reached the cytoplasm. Replication of many complex retroviruses therefore is dependent upon the activity of a virally-encoded regulatory protein, known as Rev or Rex, whose function is to allow specific viral RNAs to be exported from the nucleus into the cytoplasm (2,18,19). Proteins of this type are translocated into the nuclei of infected cells, where they bind selectively to singly spliced and unspliced viral transcripts. In each case, binding occurs at a discrete *cis*-acting sequence, known as the Rev (or Rex) response element (RRE), in the viral RNAs. As a result of this interaction, the bound nuclear RNAs are released into the cytoplasm before splicing is completed, enabling them to be translated to produce virion proteins, and so transactivating viral replication. The exact mechanism of Rev or Rex action is unknown, but is thought to involve specific effects on splicing and/or transport of RNA (1,3, 4,10,11,13).

The Rev protein from human immunodeficiency virus type 1 (HIV-1) was the first of these post-transcriptional transactivators to be identified, and remains the best characterized protein of this type (reviewed in 2). Several laboratories have carried out systematic mutagenesis in order to identify essential functional domains in the HIV-1 Rev protein (see, for example, 6,12,15,16,22). The results indicate that sequences in the N-terminal half of HIV-1 Rev are sufficient for specific RNA binding, nuclear translocation, and protein/protein interactions among Rev monomers. However, biological activity of the protein also requires a C-terminal region known as the effector domain (6,12,15,16). This effector domain is thought to mediate contacts between Rev and an unidentified cellular cofactor, which may be part of the cellular RNA splicing or transport apparatus.

Detailed mutational analysis of the HIV-1 effector domain (14) has disclosed that four critically-spaced leucine residues clustered within a region spanning approximately 11 amino

acids are essential for its activity, whereas all other residues in and around this region are dispensable. Moreover, sequence comparisons with Rev-like proteins from several other unrelated retroviruses reveals that each contains a similar short cluster of leucines or other hydrophobic amino acids (7,14), and domain-swapping experiments indicate that each of these regions can functionally replace the effector domain of HIV-1 Rev (7,14,21, and Hope et al., manuscript in preparation). These findings have suggested that all Rev-like proteins might contain such leucine-rich effector regions.

However, the Rev-like proteins from two complex retroviruses – feline immunodeficiency virus (FIV) and equine infectious anemia virus (EIAV) – have appeared to be exceptional in this regard. Although both these proteins exhibit biological properties similar to those of other Rev proteins (9,17,20), their published sequences do not include any recognizable clusters of leucines or other hydrophobic residues that might indicate effector activity. We therefore set out to determine whether the EIAV and FIV Rev proteins contain sequences that are functionally equivalent to the HIV-1 effector domain.

Methods

We measured Rev activity by using a transient transfection assay in which CV1 cells are co-transfected with an HIV-1 Rev expression vector along with a Rev-inducible chloramphenicol acetyltransferase (CAT) reporter plasmid (5,6,8). CAT induction in this assay is dependent upon sequences in the N-terminal half of Rev (which recognize an HIV-1 RRE in transcripts produced from the reporter plasmid), and also requires an intact effector domain. Thus, the CAT response is abolished when sequences encoding the native effector domain (residues 78-114) are deleted from the Rev vector, but can be restored by replacing these with sequences encoding functional effector regions from a number of other retroviruses (7, Hope et al., manuscript in preparation).

For the present study, we first inserted a full-length FIV Rev cDNA into the HIV-1 Rev expression vector in place of the native effector domain. As indicated in Fig. 1A, we found that this insertion restored function of the effectorless HIV-1 Rev mutant, implying that FIV Rev contains sequences that can complement the loss of HIV-1 Rev effector function. By testing progressively truncated FIV sequences in this manner, we mapped the minimal active sequences to amino acids 95-121. Insertion of this 27-residue sequence into the effectorless HIV-1 Rev yielded levels of CAT induction nearly equal to those obtained with wild-type HIV-1 protein. Specificity of the activity was confirmed by the finding that other regions from FIV Rev were inactive in the fusion assay (Fig. 1A), and that introduction of a di-codon missense mutation (AA replacing DL at positions 103 and 104) into the minimal FIV sequence abolished its effector activity (Fig. 1B).

By constructing an additional series of fusion proteins, we then tested sequences from EIAV Rev for effector activity (Fig. 2A). In this case, maximal activity was found to reside at amino acids 24-55, though a somewhat smaller region (residues 32-55) also retained substantial activity. To determine which residues within this 24-amino-acid sequence were required for effector function, we also constructed twelve different plasmids encoding mutant forms of the HIV-EIAV fusion protein in which consecutive pairs of native residues within the EIAV

effector region were replaced by pairs of alanines. As depicted in Fig. 2B, eight of the twelve mutations were found to inhibit CAT induction by more than 80%. Immunoblot analysis of transiently transfected cells confirmed the size and stability of the mutant fusion proteins (Fig. 2C).

To verify that CAT enzyme induction by the hybrid Rev proteins occurred through an effect on RNA localization, we performed Northern blot analysis of cytoplasmic RNA from the transfected cells. We found that, like wild-type Rev, the minimal HIV-EIAV and HIV-FIV fusion proteins each produced their effects by selectively inducing accumulation of unspliced RRE-containing reporter transcripts in the cytoplasm (Fig. 3).

Results

Our studies demonstrate that the FIV and EIAV Rev proteins each contain a region that can functionally replace the effector domain of HIV-1 Rev. This, together with earlier studies of other evolutionarily unrelated retroviruses (7,14,21, and Hope et al., manuscript in preparation), establishes that effector regions are present in all known Rev-like proteins; indeed, the presence of such domains may be regarded as a defining feature of this class of regulatory proteins. In every protein tested thus far, full effector activity maps to a region no more than 31 amino acids long which behaves as an autonomous domain. The finding that all such domains are functionally interchangeable is consistent with the view that all Rev proteins may act through the same regulatory pathway, perhaps by interacting with a common cellular cofactor.

Figure 4 depicts the minimal active effector peptides from all retroviral Rev proteins tested to date. Upon comparing these primary sequences, it is apparent that the EIAV and FIV domains differ in several respects from previously-characterized effector regions. First, although multiple leucines and other hydrophobic residues are present in the EIAV and FIV effectors, and may be required for function (Figs. 1B and 2B), these are not tightly clustered as in other proteins of this type. Second, the EIAV and FIV domains both contain somewhat higher percentages of polar amino acids (58% and 70%, respectively) than the other effector regions (47-53%). The disparity in basic residues is particularly striking: the EIAV and FIV peptides contain 13% and 22% basic residues, respectively, whereas the others contain only an average of 5% basic amino acids overall. Finally, although mutagenesis of the HIV-1 and HTLV-I effectors indicates that only leucines and other hydrophobic residues (perhaps including proline) are essential for their activity (14, Hope, et. al., manuscript in preparation), our analysis of the EIAV effector indicates that polar amino acids also contribute to its biological function. For example, mutations in the polar dipeptides 38,39 and 42,43 of the EIAV effector each greatly diminish its activity (Fig. 2B).

Discussion

Taken together, these data suggest that the ELAV and FIV sequences constitute a separate class of effector regions that are distinct at the level of primary sequence, but are nevertheless functionally interchangeable with the conventional leucine-rich effectors. It must be emphasized that, despite their divergent amino acid sequences, all of these effectors might conceivably fold into comparable three-dimensional structures that could be responsible for their similar biological activities. However, alternative possibilities are that polar effectors of the type found in ELAV and FIV might interact with a different site on the same putative cofactor used by the leucine-rich effectors, or with an entirely different factor in the same regulatory pathway. Comparative studies of these novel effector regions may therefore provide new insights into the mechanism of Rev protein function, and might also suggest new approaches to interdicting this essential pathway of retroviral transactivation.

References

1. **Chang, D.D., and Sharp, P.A.** 1989. Regulation by HIV Rev depends upon recognition of splice sites. *Cell* **59**: 789-795.
2. **Cullen, B. R.** 1991. Human immunodeficiency virus as a prototypic complex retrovirus. *J. Virol.* **65**: 1053-1056.
3. **Felber, B.K., Hadzopoulou-Cladaras, M., Cladaras, C., Copeland, T., and Pavlakis, G.N.** 1989. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. *Proc. Natl. Acad. Sci. U.S.A.* **86**: 1495-1499.
4. **Hammarskjöld, M.-L., Heimer, J., Hammarskjöld, B., Sangwan, I., Albert, L., and Rekosh, D.** 1989. Regulation of human immunodeficiency virus *env* expression by the *rev* gene product. *J. Virol.* **63**: 1959-1966.
5. **Hope, T. J., Huang, X., McDonald, D., and Parslow, T.G.** 1990. Steroid-receptor fusion of the HIV-1 Rev transactivator: Mapping cryptic functions of the arginine-rich motif. *Proc. Natl. Acad. Sci. U.S.A.* **87**: 7787-7791.
6. **Hope, T. J., McDonald, D., Huang, X., Low, J., and Parslow, T.G.** 1990. Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: Essential residues near the amino terminus. *J. Virol.* **64**: 5360-5366.
7. **Hope, T.J., Bond, B.L., McDonald, D., Klein, N.P., and Parslow, T.G.** 1991. Effector domains of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex are functionally interchangeable and share an essential peptide motif. *J. Virol.* **65**: 6001-6007.
8. **Huang, X., Hope, T.J., Bond, B.L., McDonald, D., Grahl, K., and Parslow, T.G.** 1991. Minimal Rev-response element for type 1 human immunodeficiency virus. *J. Virol.* **65**: 2131-2134.
9. **Kiyomasu, T., Miyazawa, T., Furuya, T., Shibata, R., Sakai, H., Sakuragi, J., Fukasawa, M., Maki, N., Hasegawa, A., Mikami, T., and Adachi, A.** 1991. Identification of feline immunodeficiency virus Rev gene activity. *J. Virol.* **65**: 4539-4542.

10. **Kjems, J., Frankel, A.D., and Sharp, P.A.** 1991. Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev. *Cell* **67**: 169-178.
11. **Lu, X., Heimer, J., Rekosh, D., and Hammarskjöld, M.L.** 1990. U1 small nuclear RNA plays a direct role in the formation of a Rev-regulated human immunodeficiency virus env mRNA that remains unspliced. *Proc. Natl. Acad. Sci. USA* **87**: 7598-7602.
12. **Malim, M.H., Böhnlein, S., Hauber, J., and Cullen, B.R.** 1989. Functional dissection of the HIV-1 Rev trans-activator -- derivation of a trans-dominant repressor of Rev function. *Cell* **58**: 205-214.
13. **Malim, M.H., Hauber, J., Le, S.-Y., Maizel, J.V., and Cullen, B.R.** 1989. The HIV-1 *rev* trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. *Nature* **338**: 254-257.
14. **Malim, M.H., McCarn, D.F., Tiley, L.S., and Cullen, B.R.** 1991. Mutational definition of the human immunodeficiency virus type 1 rev activation domain. *J. Virol.* **65**: 4248-4254.
15. **Mermer, B., Felber, B.K., Campbell, M., and Pavlakis, G.N.** 1990. Identification of trans-dominant HIV-1 Rev protein mutants by direct transfer of bacterially produced proteins into human cells. *Nucleic Acids Res.* **18**: 2037-2044.
16. **Perkins, A., Cochrane, A., Ruben, S., and Rosen, C.** 1989. Structural and functional characterization of the human immunodeficiency virus *rev* protein. *J. AIDS.* **2**: 256-263.
17. **Phillips, T. R., LaMont, C., Konings, D.A.M., Shacklett, B.L., Hamson, C.A., Luciw, P.A., and Elder, J.H.** 1992. Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus. *J. Virol.* **66**: 5464-5471.
18. **Rimsky, L., Duc Dudon, M., Dixon, E.P., and Greene, W.C.** 1989. trans-Dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator. *Nature* **341**: 453-456.
19. **Rimsky, L., Hauber, J., Dukovich, M., Malim, M.H., Langlois, A., Cullen, B.R., and Greene, W.C.** 1988. Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. *Nature* **335**: 738-740.

20. **Stephens, R.M., Derse, D., and Rice, N.R.** 1990. Cloning and Characterization of cDNAs encoding equine infectious anemia virus Tat and putative Rev proteins. *J. Virol.* **64**: 3716-3721.
21. **Tiley, L.S., Malim, M.H., and Cullern, B.R.** 1991. Conserved functional organization of the human immunodeficiency virus type 1 and visna virus Rev proteins. *J. Virol.* **65**: 3877-3881.
22. **Zapp, M.L. , Hope, T.J., Parslow, T.G., and Green, M.R.** 1991. Oligomerization and RNA binding domains of the HIV-1 Rev protein: A dual function for an arginine-rich binding motif. *Proc. Natl. Acad. Sci. USA.* **88**: 7734-7738.

Acknowledgments

This work was supported by grants AI29313 and GM43574 from the National Institutes of Health. Funding was also supported by a Medical Student Research Fellowship from the Howard Hughes Medical Institute. I am grateful to Li Zhu David Derse, Tom Phillips for their contributions to the content of this work. L.Z. was supported by a Cheng Scholar Award. I am indebted to Thomas J. Hope and Tristram G. Parslow for their patient guidance and endless answers to my questions. TJH and TGP were a Special Fellow and a Scholar, respectively, of the Leukemia Society of America. Most importantly, above all financial support, this work would never have come about without the unending educational support of both Tom Hope and Tristram G. Parslow.



633950



3 1378 00633 9504

